Business Context and Reporting Period
This Form 8-K was filed by Genprex, Inc. on February 4, 2022. The report addresses Item 5.02 regarding the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments approved by the Board of Directors.
Material Changes
The primary material change reported is the adjustment of base salaries and the approval of performance bonuses for five executive officers effective February 4, 2022, in consideration for their efforts during the 2021 fiscal year.
- Base Salary Adjustments:
- J. Rodney Varner (CEO): $564,000
- Mark Berger, MD (CMO): $467,750
- Catherine Vaczy (EVP/CSO): $462,000
- Ryan Confer (CFO): $397,000
- Hemant Kumar, PhD (CMTO): $336,375
- 2021 Fiscal Year Bonuses:
- J. Rodney Varner (CEO): $240,000
- Catherine Vaczy (EVP/CSO): $168,000
- Ryan Confer (CFO): $138,000
- Mark Berger, MD (CMO): $45,000
- Hemant Kumar, PhD (CMTO): $32,500
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items beyond the specific compensation actions detailed above.
Investor Verification Checklist
- Verify the total cash outflow impact of the approved bonuses ($623,500) against the company's current cash position.
- Confirm the effective date of the new base salary rates to assess future operating expense projections.
- Review the company's most recent 10-K or 10-Q to understand the financial context of these compensation increases relative to 2021 fiscal performance.